Unlocking Self-Potential

Proven Clinical Experience

Only ADVATE has 15+ years of experience in the real world as a latest-generation plasma/albumin-free recombinant VIII3,10

Committed to advancing hemophilia A treatments

1992
First Generation

1st genetically manufactured factor VIII.13
Ushers in the era of recombinant factor VIII treatment.

Late 1990s
Second Generation

Recombinant, with plasma-derived proteins in culture medium, but not in final formulation.

The amount of blood components used in processing was reduced, although some still remain.

Specifically, plasma proteins are still used in the cell-growth phase.10,15

2002

First needleless transfer device: BAXJECT®.13

2003
Third Generation:
ADVATE

First recombinant factor VIII free of blood-based additives, introducing the latest generation of treatment: ADVATE.10

Recombinant, with no plasma-derived proteins in culture medium or final formulation.

In 2003, ADVATE was introduced as the first recombinant factor VIII treatment to be free of blood-based additives. No plasma proteins are added at any stage of processing.3,15,16

There were no confirmed reports of viral transmission with recombinant factor VIII treatments.

2006

The redesigned BAXJECT II device allowed mixing in less than 1 minute and included built-in filters to maintain product purity.13

2007

First factor VIII 3000 IU single-vial dose.13

2010

First & only recombinant factor VIII 1700 IU single-vial dose.13

2011

First & only recombinant factor VIII with physical health-related quality of life results in the prescribing information.3

2012

First factor VIII 4000 IU single-vial dose.3

2012

First & only factor VIII 2 mL diluent option (250, 375, 500, 750, 1000, 1500, and 1700 IU).3,13




See Less

ADVATE [Antihemophilic Factor (Recombinant)] Important Information

What is ADVATE?

ADVATE is a medicine used to replace clotting factor (factor VIII or antihemophilic factor) that is missing in

SELECTED IMPORTANT RISK INFORMATION

Who should not use ADVATE?

Do not use ADVATE if you:

ADVATE [Antihemophilic Factor (Recombinant)] Important Information

What is ADVATE?

  • ADVATE is a medicine used to replace clotting factor (factor VIII or antihemophilic factor) that is missing in people with hemophilia A (also called “classic” hemophilia).
  • ADVATE is used to prevent and control bleeding in adults and children (0-16 years) with hemophilia A. Your healthcare provider (HCP) may give you ADVATE when you have surgery.
  • ADVATE can reduce the number of bleeding episodes in adults and children (0-16 years) when used regularly (prophylaxis).

ADVATE is not used to treat von Willebrand disease.

DETAILED IMPORTANT RISK INFORMATION

Who should not use ADVATE?

Do not use ADVATE if you:

  • Are allergic to mice or hamsters.
  • Are allergic to any ingredients in ADVATE.

Tell your HCP if you are pregnant or breastfeeding because ADVATE may not be right for you.

What should I tell my HCP before using ADVATE?

Tell your HCP if you:

  • Have or have had any medical problems.
  • Take any medicines, including prescription and non-prescription medicines, such as over-the-counter medicines, supplements or herbal remedies.
  • Have any allergies, including allergies to mice or hamsters.
  • Are breastfeeding. It is not known if ADVATE passes into your milk and if it can harm your baby.
  • Are or become pregnant. It is not known if ADVATE may harm your unborn baby.
  • Have been told that you have inhibitors to factor VIII (because ADVATE may not work for you).

What important information do I need to know about ADVATE?

  • You can have an allergic reaction to ADVATE. Call your HCP right away and stop treatment if you get a rash or hives, itching, tightness of the throat, chest pain or tightness, difficulty breathing, lightheadedness, dizziness, nausea or fainting.
  • Do not attempt to infuse yourself with ADVATE unless you have been taught by your HCP or hemophilia center.

What else should I know about ADVATE and Hemophilia A?

  • Your body may form inhibitors to factor VIII. An inhibitor is part of the body’s normal defense system. If you form inhibitors, it may stop ADVATE from working properly. Talk with your HCP to make sure you are carefully monitored with blood tests for the development of inhibitors to factor VIII.

What are possible side effects of ADVATE?

  • Side effects that have been reported with ADVATE include: cough, headache, joint swelling/aching, sore throat, fever, itching, unusual taste, dizziness, hematoma, abdominal pain, hot flashes, swelling of legs, diarrhea, chills, runny nose/congestion, nausea/vomiting, sweating, and rash. Tell your HCP about any side effects that bother you or do not go away or if your bleeding does not stop after taking ADVATE.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For additional safety information, click here for Prescribing Information and discuss with your HCP.

myPKFiT for ADVATE Patients Mobile Application Intended Use

  • The myPKFiT for Patients Mobile Application (“myPKFiT Mobile App”) is intended for use by patients with hemophilia A being treated with ADVATE [Antihemophilic Factor (Recombinant)] who are 16 years of age or older with a body weight of 45 kg or higher, and their caregivers.
  • The myPKFiT Mobile App is designed to make it convenient for you to record your infusion and bleed events, track your estimated Factor VIII levels following a prophylactic infusion, and export the data for review by your healthcare provider (“HCP”).
  • Your HCP can use the myPKFiT software to generate ADVATE dosage amount and frequency recommendations for routine prophylaxis using your age, body weight information, and laboratory tests that measure your Factor VIII clotting activity. Using myPKFiT software, HCPs can evaluate various prophylaxis dose regimens tailored to your individual needs and treatment plan.
  • myPKFiT Mobile App should only be used by hemophilia A patients treated with ADVATE, as per the ADVATE Prescribing Information.
  • myPKFiT Mobile App is not indicated for use by patients with von Willebrand disease. myPKFiT Mobile App should not be used by patients who have developed inhibitors to Factor VIII products.

myPKFiT for Patients Mobile Application is Rx only. For safe and proper use of the myPKFiT Mobile App, please refer to the complete instructions for use in the User Manual.